William G. Kaelin, Jr., M.D.
Affiliations: | Harvard Medical School, Dana Farber Cancer Institute |
Area:
medical oncology, molecular biologyWebsite:
https://www.dfhcc.harvard.edu/insider/member-detail/member/william-g-kaelin-jr-md/Google:
"William G. Kaelin, Jr."Bio:
The Nobel Prize in Physiology or Medicine 2019 was awarded jointly to William G. Kaelin Jr, Sir Peter J. Ratcliffe and Gregg L. Semenza "for their discoveries of how cells sense and adapt to oxygen availability"
http://www.nasonline.org/member-directory/members/20003143.html
https://doi.org/10.1073/pnas.1617222113
https://hms.harvard.edu/news/hms-professor-kaelin-wins-nobel-physiology-or-medicine
Cross-listing: Chemistry Tree
Parents
Sign in to add mentor| Randy L. Jirtle | research assistant | Duke | |
| David M. Livingston | post-doc | 1990 | Dana-Farber Cancer Institute (Neurotree) |
Children
Sign in to add trainee| Vijyendra Ramesh | post-doc | Dana Farber Cancer Institute, Harvard Medical School | |
| Matthew W Boudreau | post-doc | 2022- | Dana-Farber Cancer Institute and Harvard Medical School (Chemistry Tree) |
Collaborators
Sign in to add collaborator| Joan W. Conaway | collaborator | 1996-2002 | Dana Farber Cancer Institute, Harvard Medical School |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Shi DD, Lee JH, Wang AC, et al. (2023) Protocol to establish a genetically engineered mouse model of IDH1-mutant astrocytoma. Star Protocols. 4: 102281 |
| Miller JJ, Gonzalez Castro LN, McBrayer S, et al. (2022) Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. Neuro-Oncology |
| Kaelin WG. (2022) THE JEREMIAH METZGER LECTURE:VON HIPPEL-LINDAU DISEASE: INSIGHTS INTO OXYGEN SENSING, CANCER AND DRUGGING THE UNDRUGGABLE. Transactions of the American Clinical and Climatological Association. 132: 170-181 |
| Kaelin WG. (2022) Von Hippel-Lindau disease: insights into oxygen sensing, protein degradation, and cancer. The Journal of Clinical Investigation. 132 |
| Shi DD, Savani MR, Levitt MM, et al. (2022) De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma. Cancer Cell |
| Wyant GA, Yu W, Doulamis IP, et al. (2022) Mitochondrial remodeling and ischemic protection by G protein-coupled receptor 35 agonists. Science (New York, N.Y.). 377: 621-629 |
| Grubb T, Maganti S, Krill-Burger JM, et al. (2022) A Mesenchymal Tumor Cell State Confers Increased Dependency on the BCL-XL Anti-apoptotic Protein in Kidney Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Stransky LA, Vigeant SM, Huang B, et al. (2022) Sensitivity of mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway. Proceedings of the National Academy of Sciences of the United States of America. 119: e2120403119 |
| Choueiri TK, Albiges L, Atkins MB, et al. (2021) From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Kaelin WG. (2021) David M. Livingston (1941-2021). Cell. 184: 6007-6009 |